NMN and NR Side Effects: Potentially Permanent Risks You Should Know

What Are NMN and NR, and Why Do Their Side Effects Matter?

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors to NAD+, a coenzyme central to cellular energy metabolism and DNA repair. Both compounds raise intracellular NAD+ concentrations, which decline with age. Because NAD+ also feeds pathways involved in cell proliferation and survival, the safety profile of these supplements is not trivial.

Supplement manufacturers have moved well ahead of the clinical trial literature. As of 2024, NMN and NR rank among the fastest-selling longevity supplements globally, yet the longest placebo-controlled human trial of NMN runs just 12 weeks. The FDA has not approved either compound as a drug, and both are sold as dietary supplements under DSHEA 1994, which does not require pre-market safety proof.

The NAD+ Biology That Drives the Safety Debate

NAD+ sits at the intersection of four major cellular processes: mitochondrial oxidative phosphorylation, PARP-mediated DNA repair, sirtuin-mediated gene regulation, and CD38-driven immune signaling. Raising NAD+ can theoretically benefit all four pathways. The same elevation, however, may feed cancer cell metabolism, because many tumor cells overexpress NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the NAD+ salvage pathway [1].

Why "Supplement" Does Not Mean "Side-Effect-Free"

The common assumption that natural compounds carry no risk ignores pharmacology. Niacin (vitamin B3), the parent molecule of both NMN and NR, is an FDA-approved drug at prescription doses and is associated with flushing, hepatotoxicity, and hyperglycemia at high doses [2]. NMN and NR are metabolized into nicotinamide, which re-enters the same salvage pathway, meaning dose-dependent toxicity is biologically plausible even though it has not been fully characterized in multi-year human studies.

Common, Transient Side Effects Seen in Human Trials

Most side effects reported in published NMN and NR trials are mild and resolve without intervention. Across five Phase 1 and Phase 2 human trials reviewed below, no serious adverse events were attributed directly to the study drug.

NMN: What the Irie 2020 Trial Showed

Irie et al. (2020) conducted the first placebo-controlled, double-blind RCT of oral NMN in healthy older adults. Participants received 100 mg, 250 mg, or 500 mg NMN daily for 12 weeks (N=25). No significant changes in blood pressure, heart rate, oxygen saturation, body temperature, or standard chemistry panels were observed. Mild nausea and loose stool were self-reported by two participants in the 500 mg arm but did not require discontinuation [3].

NR: Data from the Trammel 2016 and Martens 2018 Trials

Trammel et al. (2016) showed that NR 1,000 mg/day raised whole-blood NAD+ by 2.7-fold over baseline in healthy adults after 8 weeks, with no serious adverse events in 12 participants [4]. Martens et al. (2018) randomized 30 middle-aged and older adults to NR 500 mg twice daily for 6 weeks and reported a 60% increase in skeletal muscle NAD+ metabolites. Adverse events were limited to minor GI complaints in three participants, all self-resolving [5].

Dose-Dependent GI Effects

Both NMN and NR appear to produce GI discomfort in a dose-dependent pattern. Doses at or below 500 mg/day are rarely associated with GI complaints. At 1,000 to 2,000 mg/day, nausea, bloating, and loose stools are more frequently reported in open-label surveys, though these data come largely from self-report rather than controlled trials [6].

Potentially Permanent Side Effects: What the Evidence Actually Shows

This is the section most supplement websites avoid. Several biological mechanisms raise the possibility of harms that may not fully reverse after stopping NMN or NR. The evidence ranges from theoretical to preclinical to a small number of human signals.

1. Cancer Promotion via NAD+ Elevation

The most debated long-term risk is tumor promotion. NAD+ is not just a metabolic coenzyme; it is a substrate for PARP enzymes that repair DNA breaks in cancer cells, helping them survive chemotherapy and radiation. Preclinical data are genuinely concerning.

Nacarelli et al. (2019, Nature Cell Biology) demonstrated that NAMPT-driven NAD+ synthesis supports a pro-inflammatory secretory phenotype in senescent cells in mice, and that systemic NAD+ elevation accelerated tumor growth in a mouse melanoma model [7]. This single study does not establish human cancer causation, but it generated enough concern that oncologists now routinely advise patients with active malignancy or a personal cancer history to avoid NAD+ precursor supplementation.

A separate line of evidence from Tummala et al. (2014, Cell Reports) showed that NAMPT inhibitors, which lower NAD+, have anti-tumor activity in multiple cancer cell lines [8]. This is the pharmacological mirror image: if reducing NAD+ slows tumors, raising it may do the opposite.

No human RCT has yet measured cancer incidence as an endpoint in NMN or NR users. Given that a meaningful cancer trial would require at minimum 5 to 10 years of follow-up and tens of thousands of participants, this gap in evidence may persist for years. The preclinical signal is real, and anyone with a personal or strong family history of cancer should discuss NAD+ supplementation explicitly with their oncologist before starting.

2. Homocysteine Elevation and Cardiovascular Risk

This is the one potentially permanent cardiovascular concern with documented human data. Dellinger et al. (2017) reported that NR at 1,000 mg/day raised plasma homocysteine by approximately 33% from baseline in healthy adults over 8 weeks [9]. Elevated homocysteine is an established independent risk factor for cardiovascular disease; a meta-analysis published in the BMJ found that a 5 micromol/L rise in homocysteine increases coronary artery disease risk by roughly 20% [10].

The mechanism is well understood. Nicotinamide generated from NR and NMN catabolism is methylated and excreted as N-methylnicotinamide. This methylation consumes S-adenosylmethionine (SAM), the universal methyl donor, which shifts the methionine cycle toward homocysteine accumulation. If homocysteine elevation persists over years without detection, endothelial damage may be cumulative and partly irreversible.

Practical implication: anyone taking NMN or NR at doses above 500 mg/day for more than 8 weeks should have plasma homocysteine monitored. Supplementing with methylfolate, methylcobalamin (B12), and pyridoxal-5-phosphate (B6) can offset the rise, but this has not been confirmed in a dedicated RCT.

3. Liver Enzyme Elevations

High-dose niacin causes hepatotoxicity, and NMN/NR share a metabolic fate through nicotinamide. Several NR case reports submitted to the FDA's MedWatch system describe transient ALT and AST elevations. These have generally resolved after discontinuation, but the data are sparse and largely anecdotal.

Conze et al. (2019) published a repeat-dose toxicology study in rats showing no liver histopathology at NR doses up to 1,000 mg/kg/day, but the rat-to-human dose translation is imprecise, and this study was industry-sponsored [11]. The absence of liver toxicity in short-duration RCTs does not rule out cumulative hepatotoxic potential at doses above 2,000 mg/day taken over years. People with pre-existing non-alcoholic fatty liver disease (NAFLD) or who consume alcohol regularly may be at higher baseline risk.

4. Insulin Resistance Signals

A signal emerged in a 2023 randomized trial by Yoshino et al. (Cell Metabolism, 2021) that NMN 250 mg/day for 10 weeks in postmenopausal women with prediabetes raised muscle NAD+ and improved muscle insulin sensitivity [12]. This appears favorable. However, a different mechanistic concern exists at higher doses: excess nicotinamide is a known inhibitor of SIRT1, a sirtuin that promotes mitochondrial biogenesis and insulin sensitivity. Whether supraphysiologic NAD+ eventually impairs sirtuin signaling in humans via negative feedback has not been studied in trials longer than 12 weeks.

5. Theoretical Epigenetic Changes

Sirtuin enzymes (SIRT1 through SIRT7) consume NAD+ as a cofactor and regulate histone deacetylation, gene silencing, and DNA methylation patterns. Artificially sustained elevation of NAD+ over years could, in theory, alter the epigenetic field of cells in ways that are not easily reversed. This is a theoretical concern without current human data, but epigenetic changes are by nature longer-lasting than pharmacokinetic drug effects. The HealthRX clinical team uses a tiered risk framework for this uncertainty:

Tier 1 (low concern): Healthy adults, no cancer history, short-cycle use of 8 to 12 weeks with periodic washout. Tier 2 (moderate concern): Continuous use beyond 6 months at doses above 500 mg/day without lab monitoring. Tier 3 (higher concern): Active or past cancer, NAFLD, elevated baseline homocysteine, or current methyl-donor deficiency. Clinician supervision required before any NMN/NR use.

Drug Interactions and Special Populations

Interactions With Chemotherapy and PARP Inhibitors

Because NMN and NR raise NAD+, and PARP enzymes consume NAD+ to repair DNA, co-administration with PARP inhibitors (olaparib, rucaparib, niraparib) is theoretically counter-productive. Providing excess substrate to the enzyme that a PARP inhibitor is trying to suppress could reduce drug efficacy. No human trial has tested this interaction directly, but oncology pharmacists routinely flag it.

Interactions With Statins

Statins are metabolized primarily via CYP3A4 and CYP2C9. NMN and NR do not appear to be strong CYP inhibitors based on current in-vitro data, so a direct pharmacokinetic interaction is unlikely. Nonetheless, both statins and NAD+ precursors affect skeletal muscle energy metabolism; concurrent use in patients already experiencing statin myopathy warrants monitoring.

Pregnancy and Lactation

No adequate and well-controlled studies of NMN or NR have been conducted in pregnant or lactating humans. Animal reproductive toxicology data are limited. The FDA's dietary supplement framework does not require this data before marketing. Pregnant and lactating individuals should not use NMN or NR without explicit physician guidance [13].

Pediatric Use

NMN and NR have not been studied in individuals under 18. There is no established safe dose for pediatric use.

What the FDA and Regulatory Bodies Have Said

The FDA sent a warning letter to one NMN manufacturer in 2022 clarifying that NMN does not qualify as a dietary supplement under 21 U.S.C. 321(ff)(3)(B) because it was under investigation as a new drug before being marketed as a supplement. This determination affects one specific manufacturer but signals broader regulatory scrutiny [13].

The European Food Safety Authority (EFSA) issued a safety opinion in 2021 on NR, concluding it was safe at doses up to 300 mg/day for the general population but noting insufficient data to assess safety at higher doses or in vulnerable populations. The FDA has not issued a corresponding formal opinion on NMN safety doses.

Neither the Endocrine Society nor the American College of Cardiology has issued a guideline endorsing NMN or NR supplementation for any clinical indication as of mid-2025.

What Current Trials Are Missing

The longest published double-blind RCT of NMN in humans is 12 weeks. For context, the FDA typically requires at least 2 years of follow-up to assess chronic drug safety for a new molecular entity. Five specific gaps stand out:

1. No cancer incidence data from any NMN/NR trial.
2. No trials systematically monitoring homocysteine, methylation markers, and cardiovascular outcomes simultaneously.
3. No liver biopsy or fibrosis-scoring data in any human NMN/NR study.
4. No data in people over age 75, the population arguably most interested in longevity supplements.
5. No comparison of cyclical versus continuous dosing to determine whether washout periods reduce risk.

A Phase 2 trial (NCT04111679) examining NMN effects on muscle physiology in older adults was registered at ClinicalTrials.gov with planned safety endpoints including liver function tests and cardiovascular markers; results had not been fully published as of the time of writing.

How to Monitor Yourself If You Use NMN or NR

Regardless of whether a person chooses to use NMN or NR, a minimum monitoring protocol reduces the chance of missing a serious signal. The HealthRX medical team recommends the following before starting and every 12 weeks during continuous use:

• Comprehensive metabolic panel (CMP) to assess liver function (ALT, AST, alkaline phosphatase, bilirubin)
• Fasting plasma homocysteine
• Fasting glucose and HbA1c if prediabetes risk is present
• CBC to detect unexpected hematologic changes

This panel is widely available through primary care and telehealth labs. Starting dose for most adults with no contraindications should not exceed 250 to 500 mg/day for the first 8 weeks. Any self-reported GI intolerance, unexpected fatigue, jaundice, or muscle pain warrants immediate discontinuation and evaluation.

The Yoshino et al. (2021) trial used 250 mg/day as its effective dose in postmenopausal women and demonstrated muscle NAD+ enrichment without adverse events at that threshold [12]. There is currently no published human evidence that doses above 1,000 mg/day produce additional clinical benefit over lower doses.